Neurocrine Biosciences, Inc.

US$164.63As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:NBIXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 14.13%
Div yield —
ROE 20.41%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.33
PE TTM 24.45
TSR TTM 14.96%
Mkt cap US$16.66B
ROIC 20.19%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$213
29.18%
(81.76%)
Hold 9|4|5|12|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
2.57
2.62
2.79
2.91
29.49%
25.59%
24.65%
17.79%
Revenue$M
867.4
906.5
924.8
945.4
12.13%
12.28%
10.45%
10.27%
Peers (US$16.66B)
Cap (US$)
PE
23.94B
21.18x
22.83B
—
16.31B
—
Capital
TTM
5Y
10Y
Leveragex
3.181
0.371
0.336
EBIT/Intx
1.080
0.191
0.186
Own earn%
144.62
(10.90)
(27.88)
Sh yield%
30.98
31.74
35.42
Owners
Insiders/Inst%
13.58
61.97
Short interest%
3.06
SBC / revenue%
5.64
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
23–27
$1 testx
−0.1
Incr. ROIC%
4